Jens Hillengass

Movement Is Medicine in Multiple Myeloma: Elucidating Exercise-Mediated Immune and Metabolic Biomarkers That Predict Treatment Response in the Bone Marrow Tumor Microenvironment

National Cancer Institute · R01

PI · $718.5K · Roswell Park Cancer Institute Corp

Investigation of the Effects of CXCR1/2 Inhibition on the Immune Microenvironment of Patients with Multiple Myeloma

National Cancer Institute · R03

Contact PI · $173.5K · Roswell Park Cancer Research Corporation

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Principal investigator · Recruiting · Phase 2

Roswell Park Cancer Institute

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Principal investigator · Recruiting · Phase 1

Roswell Park Cancer Institute

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Principal investigator · Active not recruiting · Phase 2

Roswell Park Cancer Institute

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Principal investigator · Recruiting

Roswell Park Cancer Institute